Gujarat Kidney and Super Speciality IPO Details
Gujarat Kidney and Super Speciality IPO Summary
Gujarat Kidney and Super Speciality IPO opens for subscription on 22 Dec 2025 and closes on 24 Dec 2025.The IPO will be listed on NSE, BSE with the tentative listing date set for 30 Dec 2025.
Gujarat Kidney and Super Speciality IPO price band has been fixed at ₹108 – ₹114 per share. The face value is ₹2 per share with a lot size of 128.
Gujarat Kidney and Super Speciality IPO total issue size comprises 2,20,00,000 shares (aggregating up to ₹250.80 Cr.). This includes a fresh issue of 2,20,00,000 shares (aggregating up to ₹250.80 Cr.). Pre-issue shareholding stands at 5,68,43,250, which will increase to 7,88,43,250 post-issue.
Gujarat Kidney and Super Speciality IPO carries a ₹1 (0.88%) GMP, reflecting investor sentiment.
Gujarat Kidney and Super Speciality IPO Lot Size :Retail Minimum is 1 lot (128 shares) amounting to ₹14,592. Retail Maximum is 13 lots (1,664 shares) amounting to ₹189,696. SHNI Minimum is 14 lots (1,792 shares) amounting to ₹204,288. SHNI Maximum is 68 lots (8,704 shares) amounting to ₹992,256. BHNI Minimum is 69 lots (8,832 shares) amounting to ₹1,006,848.
The Lead Managers for Gujarat Kidney and Super Speciality IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Nirbhay Capital Services Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Gujarat Kidney & Super Speciality Limited RHP.
Gujarat Kidney and Super Speciality IPO Details
Gujarat Kidney and Super Speciality IPO Subscription
Gujarat Kidney and Super Speciality IPO Application Wise Breakup (Approx)
Gujarat Kidney and Super Speciality IPO Dates
- 22 Dec 2025Opening dateOpen
- 24 Dec 2025Closing dateClose
- 26 Dec 2025Allotment Date Allotment
- 29 Dec 2025Initiation of RefundsRefund
- 29 Dec 2025Credit of SharesCredit
- 30 Dec 2025Listing dateListing
Gujarat Kidney and Super Speciality IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 128 | ₹14,592 |
| Retail Maximum | 13 | 1664 | ₹189,696 |
| SHNI Minimum | 14 | 1792 | ₹204,288 |
| SHNI Maximum | 68 | 8704 | ₹992,256 |
| BHNI Minimum | 69 | 8832 | ₹1,006,848 |
Gujarat Kidney and Super Speciality IPO Reservation
Promoter Holding
Documents
Gujarat Kidney and Super Speciality IPO Valuations
Gujarat Kidney and Super Speciality Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 61.59 | 55.34 | 20.53 | 3.87 |
| Total Income | 15.27 | 40.40 | 5.48 | 0.00 |
| Profit After Tax | 5.40 | 9.50 | 1.71 | -0.01 |
| EBITDA | 8.63 | 16.55 | 1.95 | -0.01 |
| NET Worth | 30.56 | 25.71 | 10.80 | 0.37 |
| Reserves and Surplus | 19.42 | 14.57 | 10.60 | 0.17 |
| Total Borrowing | 4.03 | 3.88 | 1.94 | |
| Amount in ₹ Crore | ||||
About Gujarat Kidney and Super Speciality IPO
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) specializes in providing multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat, India.
The company operates six multispeciality hospitals and three pharmacies as of March 20, 2025, with a total bed capacity of 400 beds, an approved capacity of 355 beds, and an operational capacity of 250 beds.
The company's hospitals include Gujarat Kidney and Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), and Ashwini Medical Centre (Anand). The company also operates Ashwini Medical Store (Anand).
Services:
- Secondary Care Services: General and surgical treatments.
- Tertiary Care Services: Super speciality surgical procedures.
Specialties:
Gujarat Superspeciality Hospital provides medical care in areas such as internal medicine, general surgery, minimally invasive procedures, orthopaedics and trauma treatment, joint replacement surgery, obstetrics and gynaecology, respiratory failure, non-interventional cardiology, diabetology, and anaesthesiology.
Workforce:
As of March 20, 2025, the company had 322 employees, including 21 full-time consultants and 32 visiting consultants. As of September 30, 2024, the company’s healthcare professionals included 47 doctors and 138 nurses.
Strength Of Gujarat Kidney and Super Speciality IPO
- Pre-eminence in renal sciences, with established sub-superspecialties in urology and strong capabilities in other specialties.
- `Right-sized', full service and strategically located hospitals leading to high return on capital.
- Ability to attract, train and retain quality medical professionals.
- Investment in infrastructure, processes and clinical excellence driving affordability, and a strong value proposition for stakeholders.
- Track record of operating and financial performance and growth.
- Professional management and experienced leadership.
Risk Of Gujarat Kidney and Super Speciality IPO
- Our Directors do not have any prior experience of being a director in any other listed company in India and this may present certain potential challenges for our Company and in the event of any material non-compliance where our Directors are held liable and responsible, we may have to appoint new directors.
- Various challenges currently faced by the healthcare industry in India may adversely affect our business, results of operations and financial condition.
- We face competition from other healthcare service providers. If we are unable to compete effectively, our business, results of operations and cash flows may be materially and adversely affected.
- There may have been certain instances of irregularities, discrepancies and non-compliances with respect to certain corporate actions taken by our Company in the past. Consequently, we may be subject to regulatory actions and penalties.
- Our subsidiary Raj Palmland Hospital Private Limited has experienced negative cash flow in the past and may continue to do so in the future, which could have a material adverse effect on our business, prospects, financial condition, cash flows and results of operations.
- Our Company has applied for registration of trademark in its name. Until such registration is granted, our Company may not be able to prevent unauthorised use of such trademark by third parties, which may lead to the dilution of our goodwill.
- There have been certain instances of delays and delay in filings of statutory returns in payment of statutory dues by our Company in the past. Any failure or delay in payment of such statutory dues may expose us to statutory and regulatory action, as well as significant penalties, and may adversely impact our business, results of operations, cash flows and financial condition.
- There are outstanding litigations involving our Company, Promoters and Directors, if determined adversely, may adversely affect our business and financial condition.
- We utilize a portion of the Net Proceeds to undertake inorganic growth for which the target may not be identified. In the event that our Net Proceeds to be utilized towards inorganic growth initiatives are insufficient for the cost of our proposed inorganic acquisition, we may have to seek alternative forms of funding.
- Acquisitions, strategic investments, partnerships or alliances may be difficult to integrate, and may adversely affect our business, financial condition and results of operations.
Objectives Gujarat Kidney and Super Speciality IPO
1. Proposed acquisition of Parekhs Hospital at Ahmedabad.
2. Part-payment of purchase consideration for the already acquired “Ashwini Medical Centre”.
3. Funding of capital expenditure requirements of the Company towards setting up of a new hospital in Vadodara.
4. Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital in Vadodara location.
5. Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by the Company
6. Funding inorganic growth through unidentified acquisitions and General Corporate Purposes.
Company Contact Details
Gujarat Kidney & Super Speciality Ltd.
Plot No. 1, City Sarve No. 1537/A,
Jetalpur Road, Gokak Mill Compound,
Alkapuri, Vadodara , Gujarat, India
Vadodara, Gujarat, 390020
Phone: +91 265 298 48
Email: info@gujaratsuperspecialityhospital.com
Website: http://www.gujaratsuperspecialityhospital.com/
Registrar Contact Details
Gujarat Kidney and Super Speciality FAQs
The Gujarat Kidney and Super Speciality IPO is a MAINBOARD public issue comprising 22000000 equity shares with a face value of ₹2 each, aggregating to a total issue size of ₹250.80 Cr.. The issue price has been fixed at ₹114 per equity share, and the minimum application size is 128 shares.
The IPO opens for subscription on 22 Dec 2025, and closes on 24 Dec 2025.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹1 (0.88%).
Quick Links
Comments
